舒洛地特注射液联合缬沙坦胶囊治疗糖尿病肾病的临床研究  

Clinical trial of sulodexide injection combined with valsartan capsule in the treatment of patients with diabetic nephropathy

作　　者：王彦[1] 唐琳[2] 

机构地区：[1]郑州大学第五附属医院内分泌科,郑州450052 [2]郑州大学第一附属医院肾内科,郑州450052

出　　处：《中国临床药理学杂志》2016年第21期1953-1956,共4页The Chinese Journal of Clinical Pharmacology

基　　金：河南省医学科技攻关计划基金资助项目(201302003)

摘　　要：目的观察舒洛地特联合缬沙坦治疗糖尿病肾病(DN)患者的临床疗效并分析其作用机制。方法将70例DN患者随机分为对照组和试验组,每组各35例,对照组采用缬沙坦治疗,每次80 mg,每天1次。在对照组治疗的基础上,试验组加用舒洛地特治疗,每次肌内注射600 LSU,每天1次,3周后改为口服250LSU,每天2次,均持续治疗一个疗程即8周。分别采用肌氨酸氧化酶法、二乙酰一肟法、电化学发光法、免疫比浊法和酶联免疫法测定超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α),对比2组临床效果。结果治疗后,试验组与对照组的总有效率分别为94.29%,71.43%,组间比较差异有统计学意义(P<0.05)。治疗前,试验组与对照组的血清hs-CRP水平分别为(8.47±2.13),(8.53±1.16)μmol·L^(-1);2组的TNF-α水平分别为(71.89±31.24),(72.38±32.47)mmol·L^(-1),组间比较差异无统计学意义(均P>0.05)。治疗后,试验组与对照组的血清hs-CRP水平分别为(3.42±1.43),(6.47±1.58)μmol·L^(-1);2组的TNF-α水平分别为(23.72±11.49),(48.47±18.63)mmol·L^(-1),与治疗前比较和组间比较差异均有统计学意义(均P<0.05)。结论舒洛地特联合缬沙坦治疗DN患者疗效显著,推测与减轻炎症反应、改善肾功能有关。Objective To observe the effect of sulodexide combined with valsartan in patients with diabetic nephropathy （DN）, and to ana- lyze the active mechanism. Methods Seventy cases of patients with DN were randomly divided into control group and treatment group, with thirty -five cases in each group. The control group were treated with valsar- tan, 80 mg one time and one time a day, while the treatment group were treated with sulodexide based on the control group, with intramuscular in- jection of 600 LSU one time, and one time a day, after 3 weeks changing to 250 LSU oral, lasting for eight weeks. The levels of indexes such as high - sensitive C reactive protein （ hs - CRP）, ~tumor necrosis factor - α （TNF- α） were detected by muscle ammonia oxidase method, diacetyl monoxime method, electrochemical luminescence, immune turbidity method and enzyme linked immunosorbent assay, respectively. The clini- cal effect was compared between two groups. Results After treatment, the total effective rate of the treatment group （94.29%） was significantly better than that of the control group （71.43%, P 〈 0. 05 ）. There were no significant differences in the levels of hs - CRP, TNF - level in treatment group and control group were （8.47 ± 2. treatment group and control group were （71.89 ± 31.24 ）, hs-CRPwith （3.42 ±1.43）,（6.47 ±1.58）μmol L- 1 between the two groups 13）, （8.53 ± 1.16） μmol （72.38 ± 32. 47 ） mmol are treatment, the hs - CRP The TNF -α level in The levels of the serum and TNF -α with （23.72 ± 11.49）, （48.47 ± 18.63 ） mmol L-1 in treatment group and control group respectively after treatment. There were significantly difference com- pared with before treatment and compared with control group （ all P 〈 0. 05 ）. Conclusion The effect of sulodexide combined with valsartan in the treatment of patients with DN is remarkable, which might be related to the decline of inflammatory reaction and the improvement of renal function.

关 键 词：舒洛地特 缬沙坦 糖尿病肾病 超敏C反应蛋白 肿瘤坏死因子-Α 

分 类 号：R972.4[医药卫生—药品]